非浸润性膀胱癌中p16及死亡相关蛋白激酶基因的甲基化

Methylation of p16 and death-associated protein kinase promoter gene regions in the blood serum of patients with non-invasive urinary bladder cancer

目的 探讨p16及死亡相关蛋白激酶（DAPK）启动子在非浸润性膀胱癌患者血清中的甲基化及意义.方法 应用甲基化特异性聚合酶链反应（MSP）检测非浸润性膀胱癌患者（实验组,25例）及健康志愿者（对照组,25例）的血清游离DNA中p16及DAPK基因启动子甲基化,分析其临床意义.结果 实验组血清中的p16基因启动子甲基化率为52%（13/25）,高于对照组的24%（6/25）,两者比较差异有统计学意义（x2=4.160,P=0.041）;实验组血清中的DAPK基因启动子甲基化率为60%（15/25）,高于对照组的32%（8/25）,两者比较差异有统计学意义（x2=3.945,P=0.047）.p16及DAPK基因启动子甲基化与吸烟史（x2=0.187,P=0.665;x2=0.109,P=0.741）、年龄（x2=0.000,P=0.991;x2=0.038,P=0.845）、性别（x2=0.746,P=0.382;x2=1.288,P=0.256）及肿瘤级别（P=1.000;P=1.000）无明显相关.结论 p16和DAPK基因启动子甲基化与非浸润性膀胱癌关系密切.

Objective To investigate p16 and death-associated protein kinase （DAPK） promoter methylation in the blood serum of patients with non-invasive urinary bladder cancer.Methods p16 and DAPK promoter methylations in blood serum of patients with non-invasive urinary bladder cancer （experimental group, n=25） and healthy volunteers （control group, n=25） were detected by methylation specific polymerease chain reaction （MSP）, and their clinical implications were analyzed.Results The methylation rate of p16 in experimental group was 52% （13/25）, higher than 24% （6/25） in control group（x2=4.160,P=0.041）;The methylation rate of DAPK in experimental group was 60% （15/25）, higher than 32% （8/25） in control group （x2=3.945,P=0.047）.Both of them had statistically significant difference.The methylation rate of p16 and DAPK was not correlated with smoking （x2=0.187, P=0.665;x2=0.109, P=0.741）, age （x2=0.000, P=0.991;x2=0.038, P=0.845）, gender （x2=0.746, P=0.382;x2=1.288, P=0.256） or the grade of tumor （P=1.000;P=1.000）.Conclusionp16 and DAPK promoter methylations are closely related to non-invasive urinary bladder cancer.